Clinical pharmacology, efficacy and safety of atazanavir: a review

Bibliography

• Available from: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3950B1_01_BristolMyersSquibb-Atazanavir.pdf
   Google Scholar
• Robinson BS, Riccardi KA, Gong YF, BMS-32632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother 2000;44(8):2093-9
   PubMed Web of Science ®Google Scholar
• Yanchunas J Jr, Langley DR, Tao L, Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors. Antimicrob Agents Chemother 2005;49(9):3825-32
   PubMed Web of Science ®Google Scholar
• Weinheimer S, Discotto L, Friborg J, Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones. Antimicrob Agents Chemother 2005;49(9):3816-24
   PubMed Web of Science ®Google Scholar
• Colonno RJ, Thiry A, Limoli K, Parkin N. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob Agents Chemother 2003;47(4):1324-33
   PubMed Web of Science ®Google Scholar
• Naeger LK, Struble KA. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients. AIDS 2006;20(6):847-53
   PubMed Web of Science ®Google Scholar
• Vora S, Marcelin AG, Gunthard HF, Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. AIDS 2006;20(1):35-40
   PubMed Web of Science ®Google Scholar
• Pellegrin I, Breilh D, Ragnaud JM, Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study). Antivir Ther 2006;11(4):421-9
   PubMed Web of Science ®Google Scholar
• Santoro MM, Bertoli A, Lorenzini P, Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients. Infection 2009;37(3):223-43
   Google Scholar
• Solas C, Colson P, Ravaux I, The genotypic inhibitory quotient: a predictive factor of atazanavir response in HIV-1-infected treatment-experienced patients. J Acquir Immune Defic Syndr 2008;48(2):177-80
   PubMed Web of Science ®Google Scholar
• Le Tiec C, Barrail A, Goujard C, Taburet AM. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet 2005;44(10):1035-50
   PubMed Web of Science ®Google Scholar
• Dickinson L, Khoo S, Back D. Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Curr Opin HIV AIDS 2008;3(3):296-305
   PubMedGoogle Scholar
• Rodriguez-Novoa S, Morello J, Barreiro P, Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring. AIDS Res Hum Retroviruses 2008;24(6):821-5
   PubMed Web of Science ®Google Scholar
• Swainston Harrison T, Scott LJ. Atazanavir: a review of its use in the management of HIV infection. Drugs 2005;65(16):2309-36
   PubMed Web of Science ®Google Scholar
• Best BM, Letendre SL, Brigid E, Low atazanavir concentrations in cerebrospinal fluid. AIDS 2009;23(1):83-7
   PubMed Web of Science ®Google Scholar
• van Leeuwen E, Ter Heine R, van der Veen F, Penetration of atazanavir in seminal plasma of men infected with human immunodeficiency virus type 1. Antimicrob Agents Chemother 2007;51(1):335-7
   PubMed Web of Science ®Google Scholar
• Ter Heine R, Hillebrand M, Rosing H, Identification and profiling of circulating metabolites of atazanavir, a human immunodeficiency virus protease inhibitor. Drug Metab Dispos 2009;37(9):1826-40
   PubMed Web of Science ®Google Scholar
• Guaraldi G, Cocchi S, Motta A, A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease. J Antimicrob Chemother 2008;62(6):1356-64
   PubMed Web of Science ®Google Scholar
• Colombo S, Buclin T, Cavassini M, Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 2006;50(11):3801-8
   PubMed Web of Science ®Google Scholar
• Zhang D, Chando TJ, Everett DW, In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005;33(11):1729-39
   PubMed Web of Science ®Google Scholar
• Burger DM, Huisman A, Van Ewijk N, The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe. Clin Pharmacol Ther 2008;84(6):698-703
   PubMed Web of Science ®Google Scholar
• Beique L, Giguere P, la Porte C, Angel J. Interactions between protease inhibitors and acid-reducing agents: a systematic review. HIV Med 2007;8(6):335-45
   PubMed Web of Science ®Google Scholar
• Falcon RW, Kakuda TN. Drug interactions between HIV protease inhibitors and acid-reducing agents. Clin Pharmacokinet 2008;47(2):75-89
   PubMed Web of Science ®Google Scholar
• Tomilo DL, Smith PF, Ogundele AB, Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy 2006;26(3):341-6
   PubMed Web of Science ®Google Scholar
• Agarwala S, Gray K, Wang Y, Pharmacokinetic effect of omeprazole on atazanavir co-administered with ritonavir in healthy subjects [abstract 658]. 612th Conference on retroviruses and Opportunictic Infections, Boston; 2005
   Google Scholar
• Agarwala S, Gray K, Eley T, Pharmacokinetic interaction between atazanavir and omeprazole in healthy subjects. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment; 2005 July, 24-27th; Rio de Janeiro; 2005
   Google Scholar
• Luber AD, Brower R, Kim D, Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers. HIV Med 2007;8(7):457-64
   PubMed Web of Science ®Google Scholar
• Klein CE, Chiu YL, Cai Y, Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir. J Clin Pharmacol 2008;48(5):553-62
   PubMed Web of Science ®Google Scholar
• DiCenzo R, Peterson DR, Cruttenden K, Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir. Antimicrob Agents Chemother 2008;52(9):3035-9
   PubMed Web of Science ®Google Scholar
• Burger DM, Agarwala S, Child M, Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrob Agents Chemother 2006;50(10):3336-42
   PubMed Web of Science ®Google Scholar
• Acosta EP, Kendall MA, Gerber JG, Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob Agents Chemother 2007;51(9):3104-10
   PubMed Web of Science ®Google Scholar
• Mallolas J, Sarasa M, Nomdedeu M, Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients. HIV Med 2007;8(2):131-4
   PubMed Web of Science ®Google Scholar
• Haas DW, Koletar SL, Laughlin L, Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr 2009;50(3):290-3
   PubMed Web of Science ®Google Scholar
• McCance-Katz EF, Moody DE, Morse GD, Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend 2007;91(2-3):269-78
   PubMed Web of Science ®Google Scholar
• Friedland G, Andrews L, Schreibman T, Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 2005;19(15):1635-41
   PubMed Web of Science ®Google Scholar
• Waters LJ, Moyle G, Bonora S, Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. Antivir Ther 2007;12(5):825-30
   PubMed Web of Science ®Google Scholar
• Seminari E, Guffanti M, Villani P, Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients. Eur J Clin Pharmacol 2005;61(7):545-9
   PubMed Web of Science ®Google Scholar
• Sekar VJ, Lefebvre E, De Marez T, Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers. Drugs R D 2007;8(4):241-8
   PubMedGoogle Scholar
• Dailly E, Tribut O, Tattevin P, Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. Eur J Clin Pharmacol 2006;62(7):523-6
   PubMed Web of Science ®Google Scholar
• Ribera E, Azuaje C, Lopez RM, Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. AIDS 2006;20(8):1131-9
   PubMed Web of Science ®Google Scholar
• Pham PA, Flexner C, Parsons T, Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir. J Acquir Immune Defic Syndr 2007;45(2):201-5
   PubMed Web of Science ®Google Scholar
• Di Giambenedetto S, De Luca A, Villani P, Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure. HIV Med 2008;9(4):239-45
   PubMed Web of Science ®Google Scholar
• von Hentig N, Kaykhin P, Stephan C, Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen. Antimicrob Agents Chemother 2008;52(6):2273-5
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Wenning LA, Mistry GC, Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis 2008;47(1):137-40
   PubMed Web of Science ®Google Scholar
• Ford J, Boffito M, Maitland D, Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients. J Antimicrob Chemother 2006;58(5):1009-16
   PubMed Web of Science ®Google Scholar
• Boffito M, Maitland D, Dickinson L, Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses. AIDS Res Hum Retroviruses 2006;22(8):749-56
   PubMed Web of Science ®Google Scholar
• King JR, Kakuda TN, Paul S, Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers. J Clin Pharmacol 2007;47(2):201-8
   PubMed Web of Science ®Google Scholar
• von Hentig N, Muller A, Rottmann C, Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen. Antimicrob Agents Chemother 2007;51(4):1431-9
   PubMed Web of Science ®Google Scholar
• Taburet AM, Piketty C, Chazallon C, Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004;48(6):2091-6
   PubMed Web of Science ®Google Scholar
• von Hentig N, Dauer B, Haberl A, Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults. Eur J Clin Pharmacol 2007;63(10):935-40
   PubMed Web of Science ®Google Scholar
• Busti AJ, Bain AM, Hall RGII, Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol 2008;51(6):605-10
   PubMed Web of Science ®Google Scholar
• Slish J, Ma Q, Zingman BS, Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring. Ther Drug Monit 2007;29(5):560-5
   PubMed Web of Science ®Google Scholar
• von Hentig N. Atazanavir/ritonavir: a review of its use in HIV therapy. Drugs Today (Barc) 2008;44(2):103-32
   PubMed Web of Science ®Google Scholar
• Available from: http://www.hiv-druginteractions.org
   Google Scholar
• Dickinson L, Boffito M, Back D, Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. J Antimicrob Chemother 2009;63(6):1233-43
   PubMed Web of Science ®Google Scholar
• Molto J, Santos JR, Valle M, Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice. Ther Drug Monit 2007;29(5):648-51
   PubMed Web of Science ®Google Scholar
• Macassa E, Delaugerre C, Teglas JP, Change to a once-daily combination including boosted atazanavir in HIV-1-infected children. Pediatr Infect Dis J 2006;25(9):809-14
   PubMed Web of Science ®Google Scholar
• Ripamonti D, Cattaneo D, Maggiolo F, Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS 2007;21(18):2409-15
   PubMed Web of Science ®Google Scholar
• O'Mara E, Randall D, Stolz R, BMS-232632: a prospective study of age and gender effects on the single-dose pharmacokinetics in healthy volunteers. 1st IAS Conference on HIV Pathogenesis and treatment; 2001 8-11 July; Buenos aeres, Argentina; 2001
   Google Scholar
• Cameron DW, Heath-Chiozzi M, Danner S, Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998;351(9102):543-9
   PubMed Web of Science ®Google Scholar
• Gulick RM, Mellors JW, Havlir D, Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337(11):734-9
   PubMed Web of Science ®Google Scholar
• Murphy RL, Sanne I, Cahn P, Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003;17(18):2603-14
   PubMed Web of Science ®Google Scholar
• Sanne I, Piliero P, Squires K, Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003;32(1):18-29
   PubMed Web of Science ®Google Scholar
• Squires K, Lazzarin A, Gatell JM, Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004;36(5):1011-9
   PubMed Web of Science ®Google Scholar
• Smith KY, Weinberg WG, Dejesus E, Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther 2008;5:5
   PubMedGoogle Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008;372(9639):646-55
   PubMed Web of Science ®Google Scholar
• Malan DR, Krantz E, David N, Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr 2008;47(2):161-7
   PubMed Web of Science ®Google Scholar
• Johnson M, Grinsztejn B, Rodriguez C, Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005;19(2):153-62
   PubMed Web of Science ®Google Scholar
• Johnson M, Grinsztejn B, Rodriguez C, 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006;20(5):711-8
   PubMed Web of Science ®Google Scholar
• Goldsmith DR, Perry CM. Atazanavir. Drugs 2003;63(16):1679-93; discussion 94-5
   PubMed Web of Science ®Google Scholar
• Chan-Tack KM, Truffa MM, Struble KA, Birnkrant DB. Atazanavir-associated nephrolithiasis: cases from the US food and drug administration's adverse event reporting system. AIDS 2007;21(9):1215-8
   PubMed Web of Science ®Google Scholar
• Couzigou C, Daudon M, Meynard JL, Urolithiasis in HIV-positive patients treated with atazanavir. Clin Infect Dis 2007;45(8):e105-8
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S, Martin-Carbonero L, Barreiro P, Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 2007;21(1):41-6
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S, Morello J, Gonzalez M, Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. AIDS 2008;22(18):2535-7
   PubMed Web of Science ®Google Scholar
• Ferreira C, Floch-Tudal C, Meir F, Atazanavir in pregnancy: influence on neonatal hyperbilirubinemia. XVth conference on retroviruses and opportunistic infections; 2008 February 3-6; Boston, USA; 2008
   Google Scholar
• Soriano V, Garcia-Gasco P, Vispo E, Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. J Antimicrob Chemother 2008;61(1):200-5
   PubMed Web of Science ®Google Scholar
• Gatell J, Salmon-Ceron D, Lazzarin A, Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis 2007;44(11):1484-92
   PubMed Web of Science ®Google Scholar
• Colafigli M, Di Giambenedetto S, Bracciale L, Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. HIV Med 2008;9(3):172-9
   PubMed Web of Science ®Google Scholar
• Mallolas J, Podzamczer D, Milinkovic A, Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. J Acquir Immune Defic Syndr 2009;51(1):29-36
   PubMed Web of Science ®Google Scholar
• Haerter G, Manfras BJ, Mueller M, Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir. AIDS 2004;18(6):952-5
   PubMed Web of Science ®Google Scholar
• McComsey G, Rightmire A, Wirtz V, Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study. Clin Infect Dis 2009;48(9):1323-6
   PubMed Web of Science ®Google Scholar
• Noor MA, Flint OP, Maa JF, Parker RA. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006;20(14):1813-21
   PubMed Web of Science ®Google Scholar
• Guffanti M, Caumo A, Galli L, Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects. Eur J Endocrinol 2007;156(4):503-9
   PubMed Web of Science ®Google Scholar
• Stanley TL, Joy T, Hadigan CM, Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients. AIDS 2009;23(11):1349-57
   PubMed Web of Science ®Google Scholar
• Busti AJ, Tsikouris JP, Peeters MJ, A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients. HIV Med 2006;7(5):317-22
   PubMed Web of Science ®Google Scholar
• Dubé MP, Shen C, Greenwald M, Mather KJ. No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial. Clin Infect Dis 2008;47(4):567-74
   PubMed Web of Science ®Google Scholar
• Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis 2009;48(4):484-8
   PubMed Web of Science ®Google Scholar
• Campbell T, Smeaton L, De Grutolla V, PEARLS (ACTG A5175): a multinational study of didanosine-EC, emtricitabine and atazanavir vs. co-formulated zidovudine/lamivudine and efavirenz for initial treatment of HIV-1 infection. XVIth International AIDS Conference; 2008 August 3-8; Mexico; 2008
   Google Scholar
• Delfraissy JF, Moreno S, Sanz-Moreno J, Efficacy and safety of 48-week maintenance with QD ATV vs ATV/r (both + 2NRTIs) in patients with VL <50 c/mL after induction with ATV/r + 2NRTIs: study AI424136. 9th International Congress on Drug Therapy in HIV Infection; 2008 9-13 November; Glasgow, UK; 2008
   Google Scholar
• Squires K, Young B, De Jesus E, Similar efficacy and tolerability of atazanavir (ATV) compared to ATV/ritonavir (RTV, r), each in combination with abacavir/lamivudine (ABC/3TC), after initial supression with ABC/3TC + ATV/r in HIV-1 infected patients: 84 week results of the ARIES trial 5th IAS Conference on AIDS pathogenesis, treatment and prevention; 2009 19-22 July; Cape Town, South Africa; 2009
   Google Scholar
• Gulnik S, Eissenstat M, Afonina E, Preclinical and early clinical evaluation of SPI-452, a new pharmacokinetic enhancer XVIth conference on retroviruses and opportunistic infections; 2009 February 8-11th; Montreal, Canada; 2009
   Google Scholar
• Rutstein R, Samson P, Kiser JJ, The PACTG 1020A protocol: atazanavir with or without ritonavir in HIV-infected infants, children, and adolescents. 14th Conference on Retroviruses and Opportunistic Infections; 2007 25-28 february; Los angeles, USA; 2007
   Google Scholar
• Conradie F, Zorilla C, Josipovic D, The safety, efficacy, and steady state pharmacokinetics of atazanavir/ritonavir (ATV/r) once daily during pregnancy: results of study AI424182. 5th IAS Conference on AIDS pathogenesis, treatment and prevention; 2009 19-22 July; Cape Town, South Africa; 2009
   Google Scholar
• Available at: http://www.aidsinfo.nih.gov
   Google Scholar